A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects
NCT ID: NCT02286882
Last Updated: 2015-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
39 participants
INTERVENTIONAL
2014-11-30
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
NCT01488877
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
NCT01200394
STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT
NCT04616027
6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
NCT00287183
Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532
NCT01369602
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
PF-06409577 or Placebo
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
Cohort 2: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
PF-06409577 or Placebo
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
Cohort 3: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
PF-06409577 or Placebo
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
Cohort 4: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
PF-06409577 or Placebo
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
Cohort 5: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
PF-06409577 or Placebo
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
Cohort 6: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
PF-06409577 or Placebo
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
Cohort 7: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
PF-06409577 or Placebo
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
Cohort 8: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
PF-06409577 or Placebo
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
Cohort 9: PF-06409577 or placebo
Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
PF-06409577 or Placebo
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-06409577 or Placebo
PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body Mass Index (BMI) of 18 to 30.5 kg/m2; and a total body weight \>50 kg
Exclusion Criteria
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Clinical Research Unit
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIH
Identifier Type: OTHER
Identifier Source: secondary_id
2014-004022-18
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
B7881001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.